Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Top-Five Wholesalers Revise Half-Year Business Forecasts Upward
November 2, 2009
- R&D NEWS IN BRIEF
November 2, 2009
- Eisai Licenses Denileukin Diftitox to TSD Japan
November 2, 2009
- Global Trials Conducted by EFPIA Member Companies Show Sharp Increase
November 2, 2009
- Teijin Sublicenses TMX-67 to Menarini in Europe
November 2, 2009
- Eliminate "Drug Lag" at Initiative of Politicians: Mr Sekiguchi
November 2, 2009
- DSP Completes Acquisition of Sepracor Inc.
November 2, 2009
- Astellas, IBL Discontinue Development of ASK8007 as Anti-RA Drug
November 2, 2009
- Pfizer Completes Acquisition of Wyeth
November 2, 2009
- Kyowa Kirin to Apply for KW-0761 Hopefully in 2011
November 2, 2009
- Roche to Strengthen Partnering in Japan: Mr McCracken
November 2, 2009
- REGULATORY NEWS IN BRIEF
November 2, 2009
- EP-Mint to Acquire Sogo SMO: EPS
November 2, 2009
- Lawmakers to Have Stronger Influence on Medical Fees
November 2, 2009
- BioWa Licenses POTELLIGENT Technology to NKTT
November 2, 2009
- 3 JMA Top Management Team Members Not Reappointed as Chuikyo Members
November 2, 2009
- Sanofi-aventis Licenses New Anti-Diabetic Agent from Wellstat Pharmaceuticals
November 2, 2009
- Price Maintenance System Essential to Make Drug Market in Japan More Attractive: Mr Kinosita
November 2, 2009
- 35 Products Approved Including Januvia/Glactiv -1-
November 2, 2009
- Korosho Increases FY2010 Budget Request to ¥28,889.4 Bil.
November 2, 2009
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…